Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 331

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 8
Chunk 331
---
 shares and 2,950,548 issued and outstanding at December 31, 2024 and 2023, respectively— 9,893 Series B convertible preferred stock, par value of $0.001 per share; no shares and 28,019,181 shares authorized at December 31, 2024 and 2023, respectively; no shares and 28,019,181 issued and outstanding at December 31, 2024 and 2023, respectively— 82,976 Class B convertible common stock, par value of $0.001 per share; no shares and 2,744,184 shares authorized at December 31, 2024 and 2023, respectively; no shares and 2,744,184 shares issued and outstanding at December 31, 2024 and 2023, respectively— 5,900 Total convertible preferred and common stock— 143,390 Stockholders' equity (deficit) (1):Common stock, par value of $0.00001 per share; 300,000,000 and 16,017,929 shares authorized at December 31, 2024 and 2023, respectively; 27,531,490 and 2,004,783 shares issued at December 31, 2024 and 2023, respectively; and 27,518,439 and 1,969,360 shares outstanding at December 31, 2024 and 2023, respectively1 10 

100

Table of Contents

Additional paid-in capital348,901 2,517 Accumulated deficit(145,014)(95,245)Accumulated other comprehensive income196 6 Total stockholders’ equity (deficit)204,084 (92,712)Total liabilities, convertible preferred and common stock and stockholders’ equity (deficit)$215,304 $70,376 

See accompanying notes to consolidated financial statements.

(1)Retroactively recast for the reverse recapitalization as described in Note 3.

101

Table of Contents

LENZ THERAPEUTICS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Year Ended December 31,20242023Operating expenses:Research and development$29,801 $59,504 Selling, general and administrative28,809 12,925 Total operating expenses58